Artificial Heart-Lung Machine Market Size & Share, By Type (Single Roller Pump and Double Roller Pump), Application (Lung Transplantation Operations, Cardiac Surgery, Acute Respiratory Failure Treatment) - Growth Trends, Regional Insights (U.S., Japan, South Korea, UK, Germany), Competitive Positioning, Global Forecast Report 2025-2034

市場の見通し:

Artificial Heart-Lung Machine Market size is forecast to grow from USD 405.01 million to USD 641.11 million between 2025 and 2034, marking a CAGR of more than 4.7%. The expected industry revenue in 2025 is USD 420.24 million.

• Base Year Value (2024): USD 405.01 million
• CAGR (2025-2034): 4.7%
• Forecast Year Value (2034): USD 641.11 million
• Historical Data Period: 2019-2024
• Largest Region: North America
• Forecast Period: 2025-2034

市場動向:

Growth Drivers & Opportunities:

The Artificial Heart-Lung Machine Market is experiencing significant growth driven by various factors. One primary driver is the growing prevalence of cardiovascular diseases globally, which has led to an increased demand for heart surgeries and, consequently, artificial heart-lung machines. As healthcare technology advances, the machines are becoming more efficient and user-friendly, attracting more medical institutions to integrate them into their operating rooms. Furthermore, increasing investments in research and development are paving the way for innovations in artificial heart-lung technology, enhancing machine capabilities and safety profiles. The rising geriatric population is another contributor; older individuals are more prone to heart diseases, thus escalating the need for these life-support systems during surgical procedures. Additionally, the expansion of healthcare services in emerging economies presents a substantial opportunity for market players to tap into new customer bases, benefiting from the rising demand for advanced medical infrastructure.

Report Scope

Report Coverage	Details
Segments Covered	Type, Application
Regions Covered	• North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA)
Company Profiled	Getinge, Medtronic, Terumo, LivaNova, MAQUET, Sorin Group, Edwards Lifesciences, ABBott Laboratories, Juray, Livanova

Industry Restraints:

Despite the positive outlook for the Artificial Heart-Lung Machine Market, several restraints could hinder its growth. High costs associated with the acquisition and maintenance of these machines pose a significant barrier, particularly in developing nations where budget constraints limit healthcare spending. The complexity of the technology often necessitates specialized training for healthcare professionals, which can be a challenge for institutions with constrained resources. There is also a risk of complications associated with the use of artificial heart-lung machines, such as infections or equipment malfunction, which can deter hospitals from adopting them widely. Regulatory hurdles in obtaining approvals for new devices may delay product launches, limiting innovation in the sector. Additionally, the growing prevalence of alternative treatment options could shift focus away from conventional heart-lung machines, impacting market growth adversely.

地域別予報:

North America

The North American artificial heart-lung machine market is primarily shaped by the United States and Canada. The U.S. is expected to dominate this market, driven by advanced healthcare infrastructure, a booming medical device industry, and significant investments in R&D for cardiovascular technologies. The increasing prevalence of heart diseases, coupled with an aging population, will further fuel the demand for heart-lung machines. Canada, while smaller in market size, is witnessing growth due to improvements in healthcare accessibility and adoption of advanced medical technologies, particularly in its larger urban centers.

Asia Pacific

In the Asia Pacific region, countries like Japan, South Korea, and China are anticipated to exhibit the largest market size and fastest growth rates. Japan is renowned for its sophisticated healthcare system and innovative medical technology, positioning it as a leader in the artificial heart-lung machine sector. South Korea is seeing rapid advancements in cardiology and a growing focus on minimizing mortality rates from cardiovascular diseases, propelling market expansion. China, with its vast population and increasing healthcare expenditures, is likely to experience exponential growth. The rising middle class and demand for advanced healthcare solutions make it a key player in the segment.

Europe

Europe's artificial heart-lung machine market is led by countries such as the United Kingdom, Germany, and France. The UK has a strong healthcare system and is at the forefront of medical device innovation, contributing to market leadership. Germany benefits from a well-established healthcare infrastructure and a reputation for high-quality medical devices, driving significant demand. France is experiencing growth due to increased investment in research and healthcare modernization. Other European nations are also expanding their market presence, influenced by growing awareness of cardiovascular health and technological advancements in medical equipment.

セグメンテーション分析:

In terms of segmentation, the global Artificial Heart-Lung Machine market is analyzed on the basis of Type, Application.

Type Segment Analysis

The Artificial Heart-Lung Machine Market can be segmented into two primary types: extracorporeal membrane oxygenation (ECMO) machines and heart-lung machines. ECMO machines are gaining traction in critical care settings due to their ability to provide prolonged cardiac and respiratory support to patients whose heart and lungs are severely compromised. This segment is expected to exhibit significant growth driven by advancements in technology and an increasing incidence of cardiac failures and pulmonary diseases. Meanwhile, traditional heart-lung machines, utilized primarily during surgeries such as open-heart procedures, continue to dominate the market. Their well-established use in hospitals contributes to a steady demand, although growth is likely to be slower compared to ECMO, given the latter’s expanding applications in emergency and pediatric care.

Application Segment Analysis

In terms of application, the market can be divided into surgical applications, emergency applications, and transport applications. Surgical applications are anticipated to account for a substantial share of the market, as heart-lung machines are indispensable during various surgical procedures, particularly cardiac surgeries. However, the emergency applications segment is projected to witness the fastest growth, propelled by the rising need for immediate life support in critical situations. The increasing prevalence of conditions requiring urgent intervention, such as severe heart and lung diseases, plays a crucial role here. Transport applications, while smaller in size, are also expected to grow, driven by an increase in the number of patients requiring transfer to specialized centers for advanced cardiac and respiratory care, especially in regions with well-developed healthcare infrastructures.

競争環境:

The competitive landscape in the Artificial Heart-Lung Machine Market is characterized by a mix of established players and emerging companies striving for innovation and market share. Key manufacturers are focusing on technological advancements, enhancing product efficacy and safety, while also expanding their geographic reach through collaborations and strategic partnerships. The market is further driven by rising incidences of cardiovascular diseases, leading to increased demand for advanced cardiac care solutions. Companies are investing in research and development to stay ahead in this rapidly evolving sector, with a strong emphasis on developing portable and miniaturized devices to improve patient outcomes. Additionally, regulatory approval processes play a significant role in shaping the competitive dynamics, influencing product launch timelines and market entry strategies.

Top Market Players

1. Medtronic

2. Abbott Laboratories

3. Terumo Corporation

4. Siemens Healthineers

5. Getinge AB

6. LivaNova PLC

7. Fresenius SE & Co. KGaA

8. Cardiovascular Systems Inc.

9. Maquet Getinge Group

10. Nihon Kohden Corporation

Table of Contents (ToC)

トピックス 1. 方法論

• 市場定義
• 研究課題
• 市場規模
  • セグメント
  • カバーされる地域
  • ベース見積もり
  • 予測計算
• データソース
  • プライマー
  • セカンダリー

トピックス 2. エグゼクティブ・サマリー

第3章 Artificial Heart-Lung Machine Market インサイト

• 市場概観
• 市場ドライバーと機会
• 市場動向と課題
• 規制風景
• 生態系分析
• 技術・イノベーション ニュース
• 主要産業開発
  • パートナーシップ
  • 合併・取得
  • 投資実績
  • 製品発売
• サプライチェーン分析
• ポーターのファイブフォース分析
  • 新入社員の脅威
  • 置換の脅威
  • 産業祭典
  • サプライヤーの力を取り戻す
  • バイヤーの力を取り戻す
• COVID-19の影響
• PESTLE分析
  • 政治風景
  • 経済景観
  • 社会景観
  • 技術景観
  • 法的景観
  • 環境の風景
• 競争力のある風景
  • 導入事例
  • 企業市場 シェア
  • 競争的な位置のマトリックス

第4章 Artificial Heart-Lung Machine Market 統計, セグメント別

• 主なトレンド
• 市場予測と予測
  • テーブル
  • チャート

*報告書のスコープ/要求によるセグメント一覧

第5章 Artificial Heart-Lung Machine Market 統計, 地域別

• 主なトレンド
  • 導入事例
  • 凹凸の影響
• 市場予測と予測
  • テーブル
  • チャート
• 地域規模
  • 北アメリカ
    • アメリカ合衆国
    • カナダ
    • メキシコ
  • ヨーロッパ
    • ドイツ
    • イギリス
    • フランス
    • イタリア
    • スペイン
    • ヨーロッパの残り
  • アジアパシフィック
    • 中国語(簡体)
    • ジャパンジャパン
    • 韓国
    • シンガポール
    • インド
    • オーストラリア
    • APACの残り
  • ラテンアメリカ
    • アルゼンチン
    • ブラジル
    • 南米の残り
  • 中東・アフリカ
    • GCCについて
    • 南アフリカ
    • MEAの残り

*リスト非排気

トピックス 6. 会社データ

• 事業案内
• 財務・業績
• 製品提供
• 戦略マッピング
  • パートナーシップ
  • 合併・取得
  • 投資実績
  • 製品発売
• 最近の開発
• 地域優位性
• SWOT分析

*報告書のスコープ・お問い合わせによる企業リスト